INDV
HealthcareIndivior Pharmaceuticals Inc · Drug Manufacturers - Specialty & Generic · $5B
What is Indivior Pharmaceuticals Inc?
Indivior Pharmaceuticals is a specialty healthcare company focused on treating opioid use disorder through prescription medications. Headquartered in North Chesterfield, Virginia, the company operates across the United States, the United Kingdom, and international markets.
Indivior develops, manufactures, and sells buprenorphine-based prescription treatments designed to help patients manage opioid dependence. The company generates revenue primarily through its branded pharmaceutical products sold to pharmacies, healthcare providers, and treatment programs. Its geographic reach spans the United States — its largest market — alongside the United Kingdom and a broader international segment, giving the business exposure to multiple healthcare systems addressing the global opioid crisis.
Indivior was founded in 2014 and is headquartered in North Chesterfield, Virginia.
- Suboxone Film — a dissolvable buprenorphine-naloxone film for opioid dependence
- Suboxone Tablet — an oral tablet formulation for opioid use disorder treatment
- Subutex Tablet — a buprenorphine-only tablet option for opioid dependence management
Is INDV a Good Stock to Buy?
UQS Score rates INDV as Good overall, reflecting a balanced profile across its five analytical pillars.
The Quality pillar registers as Good, suggesting the business demonstrates reasonable financial discipline relative to its specialty pharma peers. Valuation comes in as Attractive, meaning the stock does not appear richly priced compared to the underlying fundamentals — a notable characteristic for a branded pharmaceutical company.
Moat, Growth, and Risk all land at Neutral, indicating Indivior faces meaningful competitive and regulatory pressures without a clearly dominant market position or a strong near-term growth trajectory.
Pro members can view the exact pillar breakdown and full financial metrics behind the INDV rating. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does INDV pay dividends?
No — Indivior Pharmaceuticals Inc does not currently pay a dividend.
Indivior does not currently pay a dividend. As a specialty pharmaceutical company investing in product development and navigating a competitive branded-drug landscape, the company directs available capital toward sustaining its commercial operations and pipeline rather than returning cash to shareholders through distributions.
When does INDV report earnings?
Indivior reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Results have reflected the dynamics of a branded specialty pharma business — where pricing, volume trends, and generic competition all influence outcomes. Revenue mix across geographies adds another layer of variability to quarterly comparisons.
For the most recent quarter's results and guidance updates, visit Indivior's investor relations page directly.
INDV Price History
+199.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Indivior Pharmaceuticals Inc?
Based on Indivior Pharmaceuticals Inc's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
INDV Long-term Outlook
With Growth and Risk both rated Neutral, Indivior's fundamental outlook is one of measured stability rather than rapid expansion. The company operates in a therapeutic area with persistent demand — opioid use disorder treatment — but faces ongoing pressure from generic alternatives and evolving reimbursement environments. The Attractive Valuation label suggests the market may already be pricing in a degree of caution, which could limit downside if execution remains steady.
Growth drivers
- Persistent and underserved demand for opioid use disorder treatment across the US and internationally
- Potential geographic expansion in international markets where treatment penetration remains low
- Ongoing patient access and adherence programs supporting branded product retention
Key risks
- Generic competition eroding branded product volumes and pricing power
- Regulatory and reimbursement changes affecting specialty pharmaceutical revenues
- Concentration risk from a narrow therapeutic focus in a single drug class
INDV vs Peers
Indivior operates in a competitive specialty pharma space alongside companies with distinct therapeutic and commercial profiles.
Amneal competes across a broad generics and specialty portfolio, giving it wider therapeutic exposure but also greater pricing pressure than a branded-focused peer.
Lantheus focuses on diagnostic imaging agents, operating in a different therapeutic niche with distinct reimbursement dynamics compared to Indivior's addiction treatment focus.
Bausch Health carries a diversified branded pharmaceutical portfolio across multiple therapeutic areas, contrasting with Indivior's concentrated opioid dependence specialization.
Frequently Asked Questions
What does Indivior do?
Indivior develops and sells prescription medications for opioid use disorder. Its core products are buprenorphine-based treatments — including Suboxone Film, Suboxone Tablet, and Subutex Tablet — sold primarily in the United States, the United Kingdom, and international markets.
Does INDV pay dividends?
No, Indivior does not currently pay a dividend. The company reinvests available capital into its commercial operations and product portfolio rather than distributing cash to shareholders.
When does INDV report earnings?
Indivior follows a standard quarterly earnings cadence. For the precise reporting schedule and the most recent results, check the investor relations section of Indivior's official website.
Is INDV a good stock to buy?
UQS Score rates INDV as Good overall. The Valuation pillar is Attractive and Quality is Good, while Moat, Growth, and Risk are all Neutral. The complete pillar breakdown — available to Pro members — provides a deeper view of the trade-offs.
Is INDV overvalued?
Based on the UQS Valuation pillar, INDV is rated Attractive, suggesting the stock is not considered expensive relative to its fundamentals. This does not constitute a price prediction, but it indicates the market has not assigned a premium multiple to the shares.
How does INDV compare to its competitors?
Indivior's narrow focus on opioid dependence treatment differentiates it from broader specialty pharma peers like Amneal and Bausch Health. Compared to diagnostics-focused Lantheus, Indivior operates in a distinct therapeutic and reimbursement environment. See the full UQS comparison for side-by-side pillar ratings.
What is INDV's market cap bracket?
Indivior is classified as a mid-cap company. This places it in a segment of the market that typically carries more liquidity than small-caps but less institutional coverage than large-cap pharmaceutical peers.
Who founded Indivior?
Indivior was established in 2014 as a spin-off from Reckitt Benckiser, which had previously commercialized Suboxone. Founding and leadership details are publicly available through the company's official disclosures and investor relations materials.
Is INDV a long-term quality stock?
The UQS framework evaluates long-term quality through five pillars. INDV's Good Quality rating and Attractive Valuation are positive signals, but Neutral readings on Moat, Growth, and Risk suggest investors should weigh competitive durability carefully. Pro members can access the full long-term quality breakdown.
What is the main competitive advantage of Indivior?
Indivior's primary advantage lies in its established brand recognition within opioid use disorder treatment and its clinical relationships with addiction medicine providers. However, the UQS Moat pillar rates this as Neutral, reflecting real competitive pressure from generic alternatives.
What sector does INDV belong to?
Indivior operates in the Healthcare sector, specifically within specialty pharmaceuticals. Its focus on addiction medicine places it in a niche segment of the broader drug development and commercialization landscape.
Unlock Full INDV Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores for INDV
- ✓Access full financial metrics and trend data
- ✓Compare INDV side-by-side with competitors
- ✓See the complete risk and valuation breakdown
- ✓Track quality changes across quarterly updates
Pro Analysis
INDV — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 59.3 | 66.2 | 44.0 | 46.2 | 60.5 | 89.8 | 0.0 |
| May 20, 2026 | 59.3 | 66.2 | 44.0 | 46.2 | 60.5 | 89.6 | +0.6 |
| May 11, 2026 | 58.7 | 66.2 | 44.0 | 46.2 | 60.5 | 85.7 | +2.0 |
| May 7, 2026 | 56.7 | 61.0 | 44.0 | 45.4 | 56.1 | 86.1 | -0.5 |
| May 4, 2026 | 57.2 | 61.0 | 44.0 | 45.4 | 56.1 | 90.0 | +0.1 |
| May 3, 2026 | 57.1 | 61.0 | 44.0 | 47.2 | 56.1 | 86.9 | -0.5 |
| Apr 26, 2026 | 57.6 | 61.0 | 44.0 | 47.2 | 56.1 | 90.2 | +0.1 |
| Apr 19, 2026 | 57.5 | 61.0 | 44.0 | 47.1 | 56.1 | 89.1 | -0.2 |
| Apr 18, 2026 | 57.7 | 61.0 | 44.0 | 47.1 | 56.1 | 90.7 | -1.4 |
| Apr 2, 2026 | 59.1 | 61.0 | 44.0 | 47.1 | 56.1 | 100.0 | — |
INDV — Pillar Breakdown
Quality
— 66.2/100 (25%)Indivior Pharmaceuticals Inc shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 46.2/100 (20%)Indivior Pharmaceuticals Inc shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 60.5/100 (15%)Indivior Pharmaceuticals Inc maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 89.5/100 (15%)Indivior Pharmaceuticals Inc appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 44/100 (25%)Indivior Pharmaceuticals Inc possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for INDV.
Score Composition
Financial Data
More Stock Analysis
How is the INDV UQS Score Calculated?
The UQS (Unified Quality Score) for Indivior Pharmaceuticals Inc is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Indivior Pharmaceuticals Inc's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Indivior Pharmaceuticals Inc is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.